期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2型糖尿病治疗新策略：基于肠促胰素的治疗 被引量：2

New therapy strategy for type 2 diabetes ： Incretin based treatment
原文传递
导出
摘要 基于肠促胰素特别是胰高血糖素样肽（GLP）-1类似物的治疗方法，针对2型糖尿病的多个病理生理靶点，单药治疗和联合用药均显示出良好的疗效，并且能够避免低血糖、体重增加等不良反应，有望成为2型糖尿病治疗的新选择。 Therapy based on ineretin especially GLP-1 analogues could target on multiple defects of type 2 diabetes. Its efficacy is significant both in monotherapy and combination therapy without side effects such as hypoglycemia and weight gain. It will be an option for the treatment of type 2 diabetes.
作者 雷闽湘
机构地区 中南大学湘雅医院内分泌科
出处 《国际内分泌代谢杂志》 2009年第6期370-373,共4页 International Journal of Endocrinology and Metabolism
关键词 肠促胰素 GLP-1 2型糖尿病 利拉鲁肽 Incretin GLP-1 Type 2 diabetes mellitus Liraglutide
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献15

  • 1American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care,2008,31 ( Suppl 1 ) :S55-S60.
  • 2Guillausseau PJ, Meas T, Virally M, et al. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab, 2008,34( Suppl 2 ) :S43-S48.
  • 3Burcelin R, Knauf C, Cani P. Pancreatic alpha-cell dysfunction in diabetes. Diabetes Metab, 2008,34 ( Suppl 2 ) : S49-S55.
  • 4Vilsboll T, Holst JJ. Incretins,insulin secretion and type 2 diabetes mellitus. Diabetologia,2004,47:357-366.
  • 5UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type Ⅱ diabetes:a progressive disease. Diabetes, 1995,44 : 1249-1258.
  • 6Defronzo IRA, Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes ,2009,58:773-795.
  • 7Levy J, Atkinson AB, Bell PM, et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med, 1998,15:290-296.
  • 8Nauck M,Stockmann F,Ebert F,et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia, 1986,29 : 46 -52.
  • 9Kahn SE, Haffuer SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 2006,355 : 2427-2443.
  • 10DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose : a randomised controlled trial. Lancet,2006,368 : 1096-1105.

同被引文献13

  • 1Ovalle F,Bell DS.Effect of rosiglitazone versus insullin on the pancreatic β-cell function of subjects with type 2 diabetes[J].Diabetes Care,2004,27(13):2585.
  • 2U.K.Prospective Diabetes Study Group Prosppective diabetes study 16.Overview of years′ therapy of type Ⅱ diabetes:a progressive disease[J].Diabetes,1995,44(12):1249.
  • 3The Diabetes Control and Complications(DCCT) Research Group.Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial[J].Kidney Int,1995,47(17):1703.
  • 4Zhou J,Wang X,Pineyro MA,et al.Glucagon-like peptide 1 and wxwndin-4 convert pancreatic AR 42J cells into glucagon and insulin producing cells[J].Diabetes,1999,48(23):2358.
  • 5Iander M,Madsbad S,Deacon CF,et al.The metabolite generated by dipeptidy 1-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose leves in patients with type 2 diabetes[J].Diabetologia,2006,49(2):369.
  • 6Iander M,Madsbad S,Madsen JL,et al.Effect of 6-week course of glucagon-like peptide 1 on glycaemic control,insulin sensitivity,andβ-cell function in type 2 diabetes:a parallel-group study[J].Lancet,2002,359(5):824.
  • 7Schmiitz O,Russell-Jones D,Shaw J,et al.Liraglutide,a human Glp-1 analogue,reduces bodyweight in subjects with type 2 diabetes,irrespective of body mass index at base line[J].Diabetologia,2008,51(Suppl 1):P888.
  • 8Sokos,Nikolaidis LA,Mankad S,et al.Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure[J].J Card Fail,2006,12(4):694.
  • 9Fonseca V,Madsbad S,Falahati A,et al.One-daily human Glp-1 analog liraglutide reduces systoic blood pressure-a meta analysis of six dinical trials(LEAD)[J].Diabetes,2009,58(Suppl 1):545.
  • 10母义明.GLP-1对胃肠道系统的作用[J].中华内分泌代谢杂志,2010,26(6):529-532. 被引量：6

引证文献2

二级引证文献30

国际内分泌代谢杂志
2009年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部